If You’re Unhappy With Your Filler, What Should Be Assessed First?

The first question is whether the problem is actually being caused by the filler.

Excess volume, asymmetry, unwanted spread of filler, swelling, nodules, inflammation and changes in the surrounding tissues can sometimes look similar. The same distinction matters whether the concern involves the lips, tear trough or under-eye area, cheeks, or another previously treated region.

The material used, the anatomical layer in which it was placed, how long it has been present and whether a complication is involved can all change the appropriate treatment. This becomes particularly important in areas that have been treated repeatedly or contain older filler.2367

Can Every Filler Be Dissolved With Hyaluronidase?

No. Hyaluronidase breaks down hyaluronic acid, or HA, fillers.

Fillers made from materials such as calcium hydroxylapatite, PLLA, PMMA or silicone cannot be dissolved with hyaluronidase. Problems involving these products require an approach based on the material and the type of complication.237

If the product used is unknown, knowing only that “filler was injected” is not enough. The amount of material, its anatomical location and how long it has been present may also affect the decision.

Does All of the Filler Need to Be Dissolved?

No. In some cases, reducing only the problematic area may be enough.

If excess volume or unwanted filler is limited to a specific area, targeted or partial dissolving may be considered.

The exact percentage of filler that will disappear cannot be predicted in advance. The characteristics of the product, its distribution through the tissues and how effectively it comes into contact with hyaluronidase all influence the response.12

How Much Hyaluronidase Is Needed, and Is One Session Enough?

There is no universal hyaluronidase dose formula that applies to every patient.

Filler composition, cross-linking, amount, anatomical location and contact between the enzyme and the filler all influence the response. A rule such as “X units for every 1 mL of filler” therefore cannot be applied reliably across different products and situations.123

In a 2024 study focused mainly on the area around the eyes (the periocular region), additional hyaluronidase was required after the first treatment in 24% of applications. The study found no significant difference in outcome between the commonly used concentrations of 75 and 150 U/mL, and the authors could not establish a single optimal dosing strategy.1

This was a retrospective, single-centre study. Its findings should not be interpreted as universal success or retreatment rates for filler elsewhere in the face.

Is Ultrasound Necessary Before Dissolving Filler?

No. Ultrasound is not necessary in every filler-dissolving case.

If the filler location and the nature of the problem are sufficiently clear from the clinical history and examination, imaging may add little useful information.

Ultrasound becomes more useful when the filler type or location is uncertain, when older filler has been placed across multiple tissue layers, when a nodule is present, when previous dissolving has not produced the expected result, or when a more targeted intervention is being considered.89

Ultrasound can help show the anatomical layer, distribution and relationship of filler to the surrounding tissues. It cannot reliably identify the exact filler brand or material in every case.89

Can Filler Still Be Present Years Later?

Yes. Some hyaluronic acid fillers can still be visible on imaging years after treatment.

MRI and other imaging studies have documented long-lasting HA filler. This does not mean that every filler remains unchanged for years. Product characteristics, treatment area, volume, anatomical placement and individual tissue factors can all influence persistence.1011

Finding residual filler on imaging is also not, by itself, a reason to dissolve it. The important question is whether the remaining material is actually related to the current concern.

Why Doesn’t Hyaluronidase Always Work as Expected?

Because the result depends on more than the dose.

The material may not be hyaluronic acid. The filler may lie in a different anatomical layer than expected, or the structure thought to be filler may not actually be filler.

Different HA fillers also vary in their susceptibility to hyaluronidase. Multilayer placement, fibrosis or inadequate contact between the enzyme and the target material can further affect the response.23

If a previous dissolving treatment has not worked as expected, simply repeating the same treatment may be less useful than reassessing why the first treatment failed.

What Are the Options Besides Hyaluronidase?

Some filler problems require a different treatment.

In selected superficial or localised deposits, aspiration or mechanical removal may be considered. If an abscess or infection is present, drainage and infection management may take priority. Some complications involving permanent or semi-permanent fillers may require surgical treatment.67

None of these methods is a routine next step after unsuccessful dissolving. The appropriate treatment depends on the material involved, its anatomical location and the nature of the problem.

What Are the Risks of Hyaluronidase?

Local reactions can occur after hyaluronidase treatment, and allergic reactions are possible although uncommon.

Swelling, redness, tenderness and bruising are among the local reactions that may occur. Previous exposure to hyaluronidase and a history of certain bee or wasp venom allergies may also be relevant when assessing risk.412

Hyaluronidase can affect naturally occurring hyaluronic acid in the tissues as well as HA filler. However, strong human evidence demonstrating permanent tissue loss after aesthetic hyaluronidase use is currently lacking.14

What Is “Post-Hyaluronidase Syndrome”?

The term has been used to describe concerns such as hollowing, laxity or deterioration in skin quality after filler dissolving.

In a 2024 periocular study, adverse aesthetic changes of this type were recorded after 18% of 157 treatments. They were associated with a longer history of filler treatment and greater previous filler volume, while no association was demonstrated with the hyaluronidase dose or the two main concentrations studied.1

The study was retrospective and conducted at a single centre. The term does not represent a standardised clinical syndrome, and the effects of ageing, long-standing filler volume, previous tissue changes and hyaluronidase cannot be reliably separated.

At present, “post-hyaluronidase syndrome” should therefore not be regarded as an independently validated and established clinical diagnosis.

When Is the Problem More Than Simple Filler Dissolving?

Suspected infection, inflammatory nodules, granuloma or vascular complications change the clinical problem.

In these situations, focusing only on how much filler remains is not enough. An infection or abscess requires management of the infection, while complications involving non-HA materials require treatment appropriate to the material and the problem.67

This article focuses on elective filler problems and does not cover the treatment of vascular occlusion in detail.

When Can Filler Be Replaced After Dissolving?

There is no single waiting period that is appropriate for everyone.

The biological activity of hyaluronidase decreasing, swelling and inflammation resolving, and the tissues becoming suitable for reliable aesthetic reassessment are not the same event.

Before new filler is considered, the degree of swelling or inflammation, any remaining material, the condition of the tissues and the reason for the original problem all matter.

There is therefore no universal rule that filler should always be replaced a specific number of hours, days or weeks after hyaluronidase.413

What Is the Next Sensible Step?

The next step depends on what is actually causing the problem.

If the concern is caused by hyaluronic acid filler, hyaluronidase may be appropriate. If the material, location or diagnosis is uncertain, further assessment — and in selected cases ultrasound — may provide more useful information before another treatment is chosen.

Older or multilayer filler, nodules, inflammation, non-HA material or a previous unsuccessful dissolving attempt may point toward a different strategy rather than simply using more hyaluronidase.

References

  1. Wilde CL, Jiang K, Lee S, Ezra DG. The Posthyaluronidase Syndrome: Dosing Strategies for Hyaluronidase in the Dissolving of Facial Filler and Independent Predictors of Poor Outcomes. Plast Reconstr Surg Glob Open. 2024;12:e5765. doi:10.1097/GOX.0000000000005765
  2. Borzabadi-Farahani A, Mosahebi A, Zargaran D. A Scoping Review of Hyaluronidase Use in Managing the Complications of Aesthetic Interventions. Aesthetic Plast Surg. 2024;48:1193–1209. doi:10.1007/s00266-022-03207-9
  3. Kroumpouzos G, Treacy P. Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations. JMIR Dermatol. 2024;7:e50403. doi:10.2196/50403
  4. Murray G, Convery C, Walker L, Davies E. Guideline for the Safe Use of Hyaluronidase in Aesthetic Medicine, Including Modified High-dose Protocol. J Clin Aesthet Dermatol. 2021;14(8):E69–E75. PMID: 34840662. PMCID: PMC8570661.
  5. Murray G, Convery C, Walker L, Davies E. Guideline for the Management of Hyaluronic Acid Filler-induced Vascular Occlusion. J Clin Aesthet Dermatol. 2021;14(5):E61–E69. PMID: 34188752. PMCID: PMC8211329.
  6. Convery C, Davies E, Murray G, Walker L. Delayed-onset Nodules (DONs) and Considering their Treatment following use of Hyaluronic Acid (HA) Fillers. J Clin Aesthet Dermatol. 2021;14(7):E59–E67. PMID: 34840652. PMCID: PMC8570356.
  7. Jones DH, Fitzgerald R, Cox SE, et al. Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations From the American Society for Dermatologic Surgery Multidisciplinary Task Force. Dermatol Surg. 2021;47(2):214–226. doi:10.1097/DSS.0000000000002921
  8. Mlosek RK, Migda B, Skrzypek E, et al. The use of high-frequency ultrasonography for the diagnosis of palpable nodules after the administration of dermal fillers. J Ultrason. 2021;20(83):e248–e253. doi:10.15557/JoU.2020.0044
  9. Urdiales-Gálvez F, De Cabo-Francés FM, Bové I. Ultrasound patterns of different dermal filler materials used in aesthetics. J Cosmet Dermatol. 2021;20(5):1541–1548. doi:10.1111/jocd.14032
  10. Master M, Roberts S. Long-term MRI Follow-up of Hyaluronic Acid Dermal Filler. Plast Reconstr Surg Glob Open. 2022;10(4):e4252. doi:10.1097/GOX.0000000000004252
  11. Master M, Azizeddin A, Master V. Hyaluronic Acid Filler Longevity in the Mid-face: A Review of 33 Magnetic Resonance Imaging Studies. Plast Reconstr Surg Glob Open. 2024;12(7):e5934. doi:10.1097/GOX.0000000000005934
  12. Guliyeva G, Huayllani MT, Kraft C, Lehrman C, Kraft MT. Allergic Complications of Hyaluronidase Injection: Risk Factors, Treatment Strategies, and Recommendations for Management. Aesthetic Plast Surg. 2024;48(3):413–439. doi:10.1007/s00266-023-03348-5
  13. Kim HJ, Kwon SB, Whang KU, et al. The duration of hyaluronidase and optimal timing of hyaluronic acid filler reinjection after hyaluronidase injection. J Cosmet Laser Ther. 2018;20(1):52–57. doi:10.1080/14764172.2017.1293825 Animal model; it does not establish a universal waiting period in humans.
  14. Buhren BA, Schrumpf H, Gorges K, et al. Dose- and time-dependent effects of hyaluronidase on structural cells and the extracellular matrix of the skin. Eur J Med Res. 2020;25:60. doi:10.1186/s40001-020-00460-z In vitro/ex vivo human skin model; it does not establish long-term aesthetic outcomes in the face.